Takeda: Lung Neoplasms trials

The registry lists 16 Lung Neoplasms studies with Takeda as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 7Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerTerminatedNCT04844073Phase 1/2Results posted
• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02393209Phase 1/2Results posted
• Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)CompletedNCT02038647Phase 2Results posted
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesCompletedNCT01045421Phase 1/2Results posted
• A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)WithdrawnNCT05863819
• A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)WithdrawnNCT05737849
• A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionCompletedNCT05419700
• A Chart Review Study of Adults With Advanced NSCLCCompletedNCT05207423
• A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788WithdrawnNCT04576208Phase 2
• An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT02784158
• Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior TherapyCompletedNCT00343720Phase 2
• Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTerminatedNCT00064636Phase 1
• Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00051974Phase 2
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1